UPCC 24922 First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS viral oncogene homolog (NRAS) Mutated Solid Tumors
Brief description of study
Please refer to Protocol Section 5 (Trial Objectives) Please refer to Protocol 6.2.1 (Phase 1 Primary Endpoints) and Protocol Section 6.2.4 (Phase 2 Primary Endpoints) Please refer to Protocol 6.2.2 (Phase 1 Secondary Endpoint) and Protocol Section 6.2.5 (Phase 2 Secondary Endpoints)
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
09 Mar 2024.
Study ID: 852790
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
